Cell cycle disturbances in mucopolysaccharidoses: Transcriptomic and experimental studies on cellular models. Issue 18 (September 2022)

• Record Type: Journal Article
• Authors: Brokowska, Joanna; Gaffke, Lidia; Pierzynowska, Karolina; Cyske, Zuzanna; Węgrzyn, Grzegorz
• Is Part Of: Experimental biology and medicine. Volume 247:Issue 18(2022)
• Page Start: 1639
• Page End: 1649
• Publication Date: 2022-09
• Subjects: Mucopolysaccharidosis -- cell cycle -- cyclins -- pathomechanism -- enzyme replacement therapy -- substrate reduction therapy; Physiology -- Periodicals; Biology, Experimental -- Periodicals; Medicine, Experimental -- Periodicals; 610.72
• DOI: 10.1177/15353702221114872
• Languages: English
• ISSNs: 1535-3702

Abstract

Mucopolysaccharidoses (MPS) are a group of lysosomal storage diseases caused by defects in genes coding for proteins involved in degradation of glycosaminoglycans (GAGs). These complex carbohydrates accumulate in cells causing their serious dysfunctions. Apart from the physical GAG storage, secondary and tertiary changes may contribute significantly to the pathomechanism of the disease. Among processes which were not systematically investigated in MPS cells to date there is the cell cycle. Here, we studied perturbances in this crucial cellular process in majority of MPS types. Transcriptomic analyses indicated that expression of many genes coding for proteins involved in the cell cycle is dysregulated in all tested MPS cells. Importantly, levels of transcripts of particular genes were changed in the same manner (i.e. either up- or down-regulated) in most or all types of the disease, indicating a common mechanism of the dysregulation. Flow cytometric studies demonstrated that the cell cycle is disturbed in all MPS types, with increased fractions of cells in the G0 /G1 phase in most types and decreased fractions of cells in the G2 /M phase in all types. We found that increased levels of cyclin D1 and disturbed timing of its appearance during the cell cycle may contribute to the mechanism of dysregulation of this process in MPS. Reduction of GAG levels by either a specific enzyme or genistein-mediated inhibition of synthesis of these compounds improved, but not fully corrected, the cell cycle in MPS fibroblasts. Therefore, it is suggested that combination of the therapeutic approaches devoted to reduction of GAG levels with cyclin D1 inhibitors might be considered in further works on developing effective treatment procedures for MPS.